Pulmonary embolism

193,998views

Pulmonary embolism

Watch later

Watch later

Coronary artery disease: Clinical
Inflammatory bowel disease: Pathology review
Crohn disease
Ulcerative colitis
Inflammatory bowel disease: Clinical
Macrocytic anemia: Pathology review
Anemia: Clinical
Extrinsic hemolytic normocytic anemia: Pathology review
Microcytic anemia: Pathology review
Sideroblastic anemia
Autoimmune hemolytic anemia
Iron deficiency anemia
Non-hemolytic normocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Anemia of chronic disease
Folate (Vitamin B9) deficiency
Pancreatitis: Pathology review
Pancreatitis: Clinical
Acute pancreatitis
Chronic pancreatitis
Superior mesenteric artery syndrome
Diverticulosis and diverticulitis
Diverticular disease: Pathology review
Diverticular disease: Clinical
Appendicitis: Clinical
Appendicitis
Appendicitis: Pathology review
Irritable bowel syndrome
Anatomy of the abdominal viscera: Large intestine
Vitamin B12 deficiency
Myocardial infarction
ECG cardiac infarction and ischemia
Clot retraction and fibrinolysis
Platelet plug formation (primary hemostasis)
Erythropoietin
Coagulation (secondary hemostasis)
Atrial fibrillation
Anticoagulants: Warfarin
Heart failure
Heart failure: Pathology review
Heart failure: Clinical
Ventricular fibrillation
Ventricular tachycardia
Class III antiarrhythmics: Potassium channel blockers
Atrial flutter
Ventricular arrhythmias: Pathology review
Supraventricular arrhythmias: Pathology review
Acute kidney injury: Clinical
Kidney stones: Pathology review
Kidney stones
Glomerular filtration
Long QT syndrome and Torsade de pointes
Hyperkalemia
Hyperkalemia: Clinical
Chronic kidney disease
Chronic kidney disease: Clinical
Hyperphosphatemia
Hypercalcemia
Kidney stones: Clinical
Renal failure: Pathology review
Diabetes mellitus: Clinical
Metabolic acidosis
Class I antiarrhythmics: Sodium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Class II antiarrhythmics: Beta blockers
Positive inotropic medications
Hyponatremia: Clinical
Hyponatremia
Hypernatremia: Clinical
Hypernatremia
Chronic obstructive pulmonary disease (COPD): Clinical
Obstructive lung diseases: Pathology review
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Emphysema
Pulmonary hypertension
Cor pulmonale
Chronic bronchitis
Muscarinic antagonists
Asthma: Clinical
Asthma
Pulmonary embolism
Deep vein thrombosis and pulmonary embolism: Pathology review
Venous thromboembolism: Clinical
Pneumonia: Pathology review
Pneumonia
Pneumonia: Clinical
Ventilation-perfusion ratios and V/Q mismatch
Shock: Clinical
Shock: Pathology review
Shock
Factor V Leiden
Anticoagulants: Heparin
Hyperthyroidism medications
Hyperthyroidism: Pathology review
Hyperthyroidism: Clinical
Hypothyroidism and thyroiditis: Clinical
Hypothyroidism: Pathology review
Hypothyroidism medications
Pheochromocytoma
Adrenal masses: Pathology review
Renal artery stenosis
Hyperaldosteronism
Respiratory distress syndrome: Pathology review
Acute respiratory distress syndrome: Clinical
Diabetes insipidus and SIADH: Pathology review
Pericardial disease: Clinical
Dementia and delirium: Clinical
Dementia with Lewy bodies
Alzheimer disease
Parkinson disease
Anti-parkinson medications
Traumatic brain injury: Clinical
Concussion and traumatic brain injury
Brown-Sequard Syndrome
Cauda equina syndrome
Meningitis
Myasthenia gravis
Multiple sclerosis
Stroke: Clinical
Cerebral vascular disease: Pathology review
Alcohol use disorder
Seizures: Clinical

Transcript

Watch video only

A pulmonary embolism happens when an embolus, which is a type of blockage, suddenly gets lodged inside a pulmonary artery.

Depending on which pulmonary artery or arteries are affected by the blockage, that can seriously decrease the amount of oxygenated blood that gets out to the body.

Normally, blood makes it back to the heart from all of the tissues and organs through a network of veins that merge over and over.

Superficial veins drain blood into deep veins, which rely on the skeletal muscle pump to move blood forward. The way it works is that the surrounding skeletal muscles compress the vein and propel blood forward, and the veins prevent blood from moving backwards by using one-way valves.

Ultimately, all of the blood ends up in the superior or inferior vena cava and dumps into the right atrium.

From there the blood goes into the right ventricle and gets pumped into pulmonary artery and eventually into the lungs.

The pulmonary artery splits at a spot called the pulmonary saddle, which looks like a bit like a horse saddle, and then the right and left pulmonary arteries enter their respective lungs.

Subsequent branches off the pulmonary artery lead to smaller and smaller arteries, then arterioles, and finally capillaries that form nets around the alveoli, which is where gas exchange occurs.

When a pulmonary embolism happens, a blockage in any of the arteries leads to a decrease in blood flow to lung tissue downstream.

The majority of the time, this blockage is caused by a broken off piece of a blood clot commonly associated with deep vein thrombosis.

A deep vein thrombosis most commonly develops in the lower legs, below the knee, although a blood clot can form in both superficial and deep veins and also in other parts of the body as well.

Normally, the process starts with damage to the endothelium, or inner lining of blood vessel walls, after which there’s an immediate vasoconstriction or narrowing of the blood vessel which limits the amount of blood flow.

After that, some platelets adhere to the damaged vessel wall, and become activated by collagen and tissue factor, which are proteins that are normally kept separated from the blood by an intact endothelium.

These platelets then recruit additional platelets to form a platelet plug. This formation of the platelet plug is called primary hemostasis.

After that, the coagulation cascade is activated.

First off in the blood there’s a set of clotting factors, most of which are proteins synthesized by the liver, and usually these are inactive and just floating around in the blood.

The coagulation cascade starts when one of these proteins gets proteolytically cleaved.

This active protein then proteolytically cleaves and activates the next clotting factor, and so on.

The final step is activation of the protein fibrinogen to fibrin, which deposits and polymerizes to form a mesh around the platelets.

So these steps leading up to fibrin reinforcement of the platelet plug make up the process called secondary hemostasis and results in a hard clot at the site of the injury.

This cascade has a huge degree of amplification and takes only a few minutes from injury to clot formation.

So the activation of the cascade is carefully controlled by anticoagulation proteins that target and inactivate key clotting factors.

For example, antithrombin inactivates Factors IXa, Xa, XIa, XIIa, VIIa and thrombin while protein C inactivates Factors Va and VIIIa.

As the clot grows in size, it limits the amount of blood able to pass by, and pressure in the vein increases.

Usually the clot might start naturally breaking down, for example, enzymes like plasmin break down fibrin into fragments called D-dimers.

But sometimes, the increased pressure in the vein can cause a part of the main clot to break free, becoming a thromboembolus which can travel downstream towards the heart.

When that happens, a thromboemobolus - which is a blood clot on the move - can move from the spot of clot formation and get into the right atrium, and then into the right ventricle and get pumped into the lungs where it can get lodged some place - causing a pulmonary thromboembolism. This is a life-threatening situation because it literally blocks blood from getting into the lungs to pick up oxygen.

If there’s no blood flowing past an alveoli, then that means there are alveoli that are getting ventilated with fresh air but not getting perfused with blood. We call this a ventilation perfusion mismatch or a V/Q mismatch.

The body needs oxygenated blood to function and can therefore only tolerate a bit of a V/Q mismatch, before the lungs are no longer able to meet the needs of the body.

The amount of V/Q mismatch ultimately depends on the number, size, and location of the pulmonary thromboembolisms, which tells us the amount of lung tissue that’s being denied blood flow.

A physiologic response to all of this is hyperventilation.

Key Takeaways

Pulmonary embolism (PE) is a blockage of the lungs main artery or one of its branches by a substance that has traveled from elsewhere in the body through the bloodstream (embolism). PE most commonly results from a deep vein thrombosis (commonly a blood clot in a leg) that breaks off and migrates to the lung, a process termed venous thromboembolism (VTE). This can cause serious damage to the lung tissue and can be life-threatening.

Symptoms vary by the amount of downstream lung tissue denied blood, which creates a ventilation-perfusion mismatch. They include shortness of breath, chest pain, and coughing. PE can also cause low blood oxygen levels, which can lead to confusion, loss of consciousness, and even death. Treatment of PE typically involves supportive therapy and blood thinning medications to dissolve the clot and prevent further clots from forming. Sometimes a filter is placed in the vena cava to trap clots before they reach the lungs.

Sources

  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  3. "Pathophysiology of Disease: An Introduction to Clinical Medicine 8E" McGraw-Hill Education / Medical (2018)
  4. "CURRENT Medical Diagnosis and Treatment 2020" McGraw-Hill Education / Medical (2019)
  5. "Thrombosis" Arteriosclerosis, Thrombosis, and Vascular Biology (2014)
  6. "Acute pulmonary embolism: An update on diagnosis and management" Current Problems in Cardiology (2005)
  7. "Epidemiology, Pathophysiology, and Natural History of Pulmonary Embolism" Seminars in Interventional Radiology (2018)